---
run_id: halo-evidence-vs-diagnosis-validation-v12-vanilla-06
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
model_condition: vanilla
run_number: 6
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 2048
seed: 601
prompt_source: condition packet (vanilla) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 81621976eaf302301d88434e895bffe7f264ddbe9d86bbb0dd82120c2f65f2aa
source_packet: the frozen Advisor prompt alone, with no added material - see run-packet.md
source_packet_sha256: 81621976eaf302301d88434e895bffe7f264ddbe9d86bbb0dd82120c2f65f2aa
condition_packet_sha256: 81621976eaf302301d88434e895bffe7f264ddbe9d86bbb0dd82120c2f65f2aa
output_file: model-outputs/vanilla-06.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - vanilla (run 06)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v12-v1`, condition `vanilla`, run 6 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 601, on the frozen condition packet.

## Output

I recommend the **Case Evidence Review**.

### The Recommendation
You should advise the CEO to commit to the Case Evidence Review. While the financial metrics look strong, they are currently "noisy" and potentially artificial—driven by temporary pricing bundles and sales-led roadmap promises rather than realized product value.

The core risk is a "Value Gap": managers like the tool for reporting/enablement, but the actual practitioners (analysts) are abandoning it or cannot justify its output to reviewers. If you scale now, you risk a massive churn event once the "bundle" honeymoon ends and procurement windows open. The Case Evidence Review is the only option that moves past proxy metrics (usage, tickets) to determine if PlanPilot is actually solving the core workflow problem or simply creating a "draft" that analysts then manually fix in secret.

### The Strongest Reason Against It
The Case Evidence Review is the slowest and most labor-intensive of the options. Unlike the Adoption Quality Sprint (which uses existing data) or the Demand Cleanroom (which tests pricing), this requires manual, qualitative auditing of case files and interviews with users. In a high-pressure environment where the executive team currently feels "aligned" and "disciplined," proposing a deep-dive audit that might debunk the current "win" could be perceived as momentum-killing or overly academic.

### Evidence That Would Change My Mind
I would pivot to the **Demand Cleanroom** if you discovered that the "bundle pricing" accounted for more than 70% of the expansion revenue. If the growth is almost entirely a result of a pricing loophole rather than product interest, you no longer have a *product-market fit* question—you have a *pricing strategy* crisis. In that scenario, validating the workflow (Case Evidence Review) is secondary to determining if anyone is actually willing to pay the full market price for the feature.
